FDA drops a hold on Halozyme study

Just days after Halozyme Therapeutics ($HALO) slammed the brakes on a study of its pancreatic cancer therapy after an independent data monitoring committee flagged a possible spike in blood clots and vessel blockages in the treatment arm, the FDA has followed up by clamping a clinical hold on PEGPH20. The latest news sliced only 3% off the biotech's share price. Investors had apparently priced in the hold after watching the company's shares plunge when Halozyme halted the study a week ago. Release